Aclarion
Open
$3.34
Prev. Close
$3.38
High
$3.34
Low
$3.34
Market Snapshot
$2.19M
-0.3
-4364.92
$54.6K
6
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
emptyResult
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Recently from Cashu
Aclarion's ACON Investments Divests Vitalis Stake, Highlighting Growth in Latin American Pharma
ACON Investments Successfully Divests Stake in Vitalis S.A.C.I. ACON Investments, a private equity firm with a strong foothold in the Latin American market, announces the successful sale of its stake…
ACON Investments Partners with KiSabor to Boost Brazilian Food Sector Growth
ACON Investments Partners with KiSabor to Propel Growth in Brazilian Food Sector ACON Investments, a private equity firm based in Washington, D.C., has entered a definitive agreement to invest in KiSa…
Aclarion Partners with ACON Investments to Boost KiSabor's Growth in Brazil’s Food Market
ACON Investments Partners with KiSabor to Propel Growth in Brazil’s Food Sector ACON Investments, a prominent private equity firm based in Washington, D.C., solidifies its commitment to the Latin Amer…
ACON Investments Acquires True Religion, Boosting Growth Prospects for Aclarion's Portfolio
ACON Investments Acquires Controlling Stake in True Religion, Signaling Growth Ambitions In a strategic move that highlights its commitment to the fashion industry, ACON Investments, L.L.C. announces…